PF-06281355 (Free base)
| CAS No. | 1435467-38-1 | Cat. No. | BCP20207 |
| Name | PF-06281355 (Free base) | ||
| Synonyms | PF06281355;PF1355;PF 1355;PF-06281355;PF 06281355; | ||
| Formula | C14H15N3O4S | M. Wt | 321.35 |
| Description | In a dose-responsive fashion, PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM). Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment. | ||
| Pathways | Others Pathway | ||
| Targets | Others | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.